Literature DB >> 22885101

Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies.

Yue Yu1, Hongling Liu, Yasuhiro Ikeda, Bruce P Amiot, Piero Rinaldo, Stephen A Duncan, Scott L Nyberg.   

Abstract

UNLABELLED: Maturation of induced pluripotent stem cells (hiPSCs) to hepatocyte-like cells (HLCs) has been proposed to address the shortage of human hepatocytes for therapeutic applications. The purpose of this study was to evaluate hiPSCs, HLCs and hepatocytes, all of human origin, in terms of performance metrics of relevance to cell therapies. hiPSCs were differentiated to HLCs in vitro using an established four-stage approach. We observed that hiPSCs had low oxygen consumption and possessed small, immature mitochondria located around the nucleus. With maturation to HLCs, mitochondria showed characteristic changes in morphology, ultrastructure, and gene expression. These changes in mitochondria included elongated morphology, swollen cristae, dense matrices, cytoplasmic migration, increased expression of mitochondrial DNA transcription and replication-related genes, and increased oxygen consumption. Following differentiation, HLCs expressed characteristic hepatocyte proteins including albumin and hepatocyte nuclear factor 4-alpha, and intrinsic functions including cytochrome P450 metabolism. But HLCs also expressed high levels of alpha fetoprotein, suggesting a persistent immature phenotype or inability to turn off early stage genes. Furthermore, the levels of albumin production, urea production, cytochrome P450 activity, and mitochondrial function of HLCs were significantly lower than primary human hepatocytes.
CONCLUSION: - hiPSCs offer an unlimited source of human HLCs. However, reduced functionality of HLCs compared to primary human hepatocytes limits their usefulness in clinical practice. Novel techniques are needed to complete differentiation of hiPSCs to mature hepatocytes.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885101      PMCID: PMC3619384          DOI: 10.1016/j.scr.2012.06.004

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  39 in total

1.  Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice.

Authors:  Silvia Espejel; Garrett R Roll; K John McLaughlin; Andrew Y Lee; Jenny Y Zhang; Diana J Laird; Keisuke Okita; Shinya Yamanaka; Holger Willenbring
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

2.  Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells.

Authors:  Zhihua Song; Jun Cai; Yanxia Liu; Dongxin Zhao; Jun Yong; Shuguang Duo; Xijun Song; Yushan Guo; Yang Zhao; Han Qin; Xiaolei Yin; Chen Wu; Jie Che; Shichun Lu; Mingxiao Ding; Hongkui Deng
Journal:  Cell Res       Date:  2009-09-08       Impact factor: 25.617

3.  Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds.

Authors:  Yunfang Wang; Cai-Bin Cui; Mitsuo Yamauchi; Patricia Miguez; Marsha Roach; Richard Malavarca; M Joseph Costello; Vincenzo Cardinale; Eliane Wauthier; Claire Barbier; David A Gerber; Domenico Alvaro; Lola M Reid
Journal:  Hepatology       Date:  2010-12-13       Impact factor: 17.425

4.  Induction of donor-specific tolerance using superagonistic CD28 antibody in rat renal allografts: regulatory T-cell expansion before engraftment may be important.

Authors:  Haruhito Azuma; Yoshitaka Isaka; Hayahito Nomi; Teruo Inamoto; Xiao-Kang Li; Tomas Hounig; Yoshitsugu Takabatake; Naotsugu Ichimaru; Naokazu Ibuki; Kunio Matsumoto; Takanobu Ubai; Yoji Katsuoka; Shiro Takahara
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

5.  Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells.

Authors:  Pau Sancho-Bru; Philip Roelandt; Nidhi Narain; Karen Pauwelyn; Tineke Notelaers; Takeshi Shimizu; Michael Ott; Catherine Verfaillie
Journal:  J Hepatol       Date:  2010-09-06       Impact factor: 25.083

6.  Mitochondrial rejuvenation after induced pluripotency.

Authors:  Steven T Suhr; Eun Ah Chang; Jonathan Tjong; Nathan Alcasid; Guy A Perkins; Marcelo D Goissis; Mark H Ellisman; Gloria I Perez; Jose B Cibelli
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

7.  Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells.

Authors:  Lyle Armstrong; Katarzyna Tilgner; Gabriele Saretzki; Stuart P Atkinson; Miodrag Stojkovic; Ruben Moreno; Stefan Przyborski; Majlinda Lako
Journal:  Stem Cells       Date:  2010-04       Impact factor: 6.277

8.  Directed differentiation of human embryonic stem cells into functional hepatic cells.

Authors:  Jun Cai; Yang Zhao; Yanxia Liu; Fei Ye; Zhihua Song; Han Qin; Sha Meng; Yuezhou Chen; Rudan Zhou; Xijun Song; Yushan Guo; Mingxiao Ding; Hongkui Deng
Journal:  Hepatology       Date:  2007-05       Impact factor: 17.425

9.  L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.

Authors:  Lars Marius Ytrebø; Rune Gangsøy Kristiansen; Hanne Maehre; Ole Martin Fuskevåg; Trine Kalstad; Arthur Revhaug; María Jover Cobos; Rajiv Jalan; Christopher F Rose
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

10.  Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny.

Authors:  T Thatava; T J Nelson; R Edukulla; T Sakuma; S Ohmine; J M Tonne; S Yamada; Y Kudva; A Terzic; Y Ikeda
Journal:  Gene Ther       Date:  2010-11-04       Impact factor: 5.250

View more
  48 in total

1.  Peripheral artery disease, calf skeletal muscle mitochondrial DNA copy number, and functional performance.

Authors:  Mary M McDermott; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Jack M Guralnik; Melina R Kibbe; Tamar S Polonsky; Lu Tian; Michael H Criqui; Lihui Zhao; James H Stein; Lingyu Li; Christiaan Leeuwenburgh
Journal:  Vasc Med       Date:  2018-05-08       Impact factor: 3.239

Review 2.  Roles of mitochondria in liver cancer stem cells.

Authors:  Ching-Wen Chang; Jeng-Fan Lo; Xin Wei Wang
Journal:  Differentiation       Date:  2019-05-30       Impact factor: 3.880

Review 3.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

4.  Cell Expansion During Directed Differentiation of Stem Cells Toward the Hepatic Lineage.

Authors:  Ravali Raju; David Chau; Dong Seong Cho; Yonsil Park; Catherine M Verfaillie; Wei-Shou Hu
Journal:  Stem Cells Dev       Date:  2016-11-01       Impact factor: 3.272

Review 5.  A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.

Authors:  A S Khazali; A M Clark; A Wells
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 6.  Hepatocyte-like cells derived from induced pluripotent stem cells.

Authors:  Namita Roy-Chowdhury; Xia Wang; Chandan Guha; Jayanta Roy-Chowdhury
Journal:  Hepatol Int       Date:  2016-08-17       Impact factor: 6.047

Review 7.  Modeling Inborn Errors of Hepatic Metabolism Using Induced Pluripotent Stem Cells.

Authors:  Behshad Pournasr; Stephen A Duncan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-17       Impact factor: 8.311

Review 8.  Application of Induced Pluripotent Stem Cells in Liver Diseases.

Authors:  Yue Yu; Xuehao Wang; Scott L Nyberg
Journal:  Cell Med       Date:  2014-04-22

Review 9.  Cellular therapy for liver disease.

Authors:  Robert C Huebert; Jorge Rakela
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

Review 10.  New and old technologies for organ replacement.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Curr Opin Organ Transplant       Date:  2013-04       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.